Cara Therapeutics Inc. (CARA) Has Broken Out To A New High On Study Results
Cara Therapeutics Inc. (CARA) announced Wednesday morning that its Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries demonstrated statistically significant reductions in pain intensity compared to placebo.
Source: RTTNews